

31 January 2023

Ticker: IXR AUCash: A\$20mProject: MakuutuMarket cap: A\$132mPrice: A\$0.03/shCountry: UgandaREC. (unc): BUYTARGET (-0.02): A\$0.15RISK RATING (unc): HIGH

Today's DQ22 update had no surprises with key points 1) Mining Lease Application (MLA) remains on track for 1Q23 (per IXR's expectations); 2) study on US downstream refinery guided for 1Q23, and 3) plans for the Makuutu demonstration plant in 2H23. Other highlights included achieving a maiden Digbee ESG rating of BB and acceptance into the UN Global Compact, both important for securing funding for an energy transition metal project. Overall we think IXR is following the right strategy – using its advantages of resource size (long-life) and permit lead time (early mover) on the mining side as leverage to capture greater margin by going downstream to separated oxides. Execution and timing, of course, are key, noting the increase in Australian clay-hosted projects (~700-800ppm), and new higher grade (1,500ppm +) projects in Brazil, listing on ASX. We maintain our BUY rating but lower our price target to A\$0.15/sh 0.75x NAV_{8%} and unchanged LT prices of US\$150/kg NdPr, US\$500/kg Dy and US\$2,200/kg Tb. Stepping back, we think there will be room for 2-3 HREE clay projects (ex-China) in the near term, and 3-5 by 2030, with a pull factor in Dy and Tb prices given the lack of new projects, so the macro remains strongly supportive. After the current price pullback, we think IXR is good value and one of the names to hold, noting it is the closest to development and could secure both the Makuutu mining license and substantially advance the (likely US) separation facility by mid-2023.

DQ22 -Mining Lease + refinery study on track for 1Q23, maiden ESG rating, A\$20m cash balance

Ionic released its DQ22 quarterly activities + cash flow report.

<u>Financial</u>: IXR ended the quarter with A\$19.6m of cash and no debt with A\$2.0m used in operating activities, A\$2.7m used in investing and A\$1.3m inflows from option exercises during the quarter.

<u>Makuutu</u>: the MLA is expected to be finalised imminently, pending internal approval of the feasibility study, and lonic expects award of the MLA later this quarter. The resettlement action plan is in advanced stages – all project affected persons (PAPs) have been identified, the ESIA was approved by the Govt, and the project is entering MOUs with PAPs to support land access.

<u>US/UK</u>: The Belfast recycling demonstration plant is on track for 1Q23 completion and first REO products in 2Q23 targeting 10 tonnes/year of separated magnet REO products. The downstream refinery study is in final stages and expected to be completed in Q1. The US is the preferred jurisdiction with several sites reviewed and a preferred location identified.

<u>ESG</u>: lonic achieved an initial overall Digbee ESG rating of BB including BB for the Makuutu project and B for corporate. The company also was accepted as a member of the United Nations Global Compact, the world's largest corporate sustainability initiative.

Model Changes: Update FX, lift unit costs, new PT A\$0.15/sh (prev A\$0.17/sh), maintain BUY

Updating cash for quarter end (A\$19.6m), spot FX (1 AUD = 0.707 USD, prev 0.65), and updating our Makuutu unit costs to US\$3.3/t mined, US\$8/t processed and US\$2/t G&A (prev US\$2.75/t, US\$6.00/t and US\$0.70/t, respectively) to account for cost inflation, we trim our NAV estimate by 9.4%, and retain our BUY rating with a price target of A\$0.15/sh based on unchanged multiples of 0.75x NAV $_{8\%}$.

Why we like Ionic

- The largest ionic clay deposit available to directly supply HREEs to Western end users
- Able to get into production by SCPe 2025
- Excellent infrastructure including highway, hydropower and reagents
- Opportunity to become an integrated upstream and midstream supplier



Catalysts

- 1Q23: Mining Permits and refinery scoping study
- 2023: SCPe pilot plant, trial mining
- 2024: SCPe first production and ramp up
- 2025: SCPe steady state production

Research

Justin Chan (London) M: +44 7554 784 688 jchan@sprott.com

Eleanor Magdzinski (Toronto) M: +1 705 669 7456 emagdzinski@sprott.com Konstantinos Kormpis (Toronto) M: +1 778-957-3623 kkormpis@sprott.com



| Ticker: IXR AU | Price / mkt cap | | A\$0.03/sh, | | | Market P/NAV: | 0.09x | | Assets: | Makuutu | |
|---|-------------------|-------------------|---------------------|------------------|---------------------|--|------------|--------------|----------|------------|---------|
| Author: J Chan / E Magdzinski | Rec / PT: | | BUY / A\$0. | 15 | | 1xNAV FD: | A\$0.27/sh | | Country: | Uganda | |
| Group-level SOTP valuation | 4Q22 | 1Q23 | | | | Resource / Reserve | Mt | ppm TREO | 000t REO | \$m insitu | |
| | | US\$m | O/ship | NAVx | A\$/sh | Measured, ind. & inf. | 532 | 640 | 340 | 21,656 | 0.37% |
| Makuutu (60%) NPV 1Q23 | | 222 | 60% | 0.75x | 0.08 | SCPe Mine Inventory | 300 | 725 | 218 | 8,854 | 0.90% |
| Makuutu MRE outside mine plan (2.5% insit | ı value) | 166 | 60% | 0.75x | 0.04 | Commodity price | Jun '22 | Jun '23 | Jun '24 | Jun '25 | Jun '26 |
| Downstream | | 415 | 100% | 0.75x | 0.11 | NdPr price (US\$/t) | 143 | 113 | 154 | 154 | 154 |
| Central SG&A & fin costs 1Q23 | | (50) | - | 0.75x | (0.01) | Share data | | () | | 50.05 | |
| Cash and restr. cash 4Q22 | | 20 | - | 0.75x | 0.01 | Basic shares (m): 3872.6 | | options (m): | | FD/FF | |
| Cash from options | | 6 | - | 0.75x | 0.00 | Ratio analysis | Jun '22 | Jun '23 | Jun '24 | Jun '25 | Jun '26 |
| Debt 4Q22 | | - | | 0.75x | | FD shares out (m) | 3,873 | 5,111 | 5,111 | 6,349 | 6,349 |
| 1xNAV8% spot fully diluted, pre-funded | | 778 | | 0.75 | 0.22 | EPS (US\$/sh) | (0.00) | (0.00) | (0.00) | (0.00) | 0.01 |
| Assumed equity raised | | 150 928 | | 0.75x | 0.02 0.15 | CFPS before w/c (US\$/sh) | (0.00) | (0.00) | (0.00) | (0.00) | 0.00 |
| 1xNAV8% spot fully funded | nine and discount | | ala. | | 0.15 | FCFPS pre growth (US\$/sh) | 0.00 | (0.00) | 0.01 | (0.02) | (0.02) |
| 1x fully funded NAVPS sensitivity to gold p | | | | #17F/lea | ¢200/l/= | FCF/sh (US\$/sh) FCF yield pre growth (US\$/sh) | (0.00) | (0.00) | (0.02) | (0.03) | (0.03) |
| Valuation (A\$/sh) | \$100/kg | \$125/kg 0.08 | \$150/kg 0.10 | \$175/kg 0.12 | \$200/kg 0.14 | , , , , , , , | 2% | (2%) | 29% | (63%) | (52%) |
| 0.50xNAV | 0.06 | | | | | FCF yield (%) | (10%) | (5%) | (47%) | (88%) | (85%) |
| 0.60xNAV | 0.08 | 0.10 0.12 | 0.12 0.15 | 0.14 0.18 | 0.16 | EBITDA margin (%) | - | - | | 14% | 27% |
| 0.75xNAV | 0.10 | | 0.15 | 0.18 | 0.21 | FCF margin (%) | | | | (356%) | (46%) |
| 1.00xNAV | 0.13 | 0.17 | | | | ROA (%) | (9%) | (4%) | (5%) | (1%) | 10% |
| Makuutu NPV8% (US\$m) | \$100/kg | \$125/kg | \$150/kg | \$175/kg | \$200/kg | ROE (%) | (10%) | (4%) | (11%) | (3%) | 22% |
| 12% discount | 22 | 78 | 134 | 189 | 245 | ROCE (%) | (10%) | (4%) | (2%) | 1% | 18% |
| 10% discount | 40 | 106 | 172 | 238 | 304 | PER (x) | (26x) | (31x) | (14x) | (26x) | 3x |
| 8% discount | 63 | 143 | 222 | 301 | 380 | P/CF (x) | (39x) | (35x) | (14x) | (57x) | 3x |
| 6% discount | 93 | 189 | 285 | 381 | 477 | EV/EBITDA (x) | (23x) | (17x) | (26x) | 25x | 3x |
| 5% discount | 111 | 217 | 324 | 430 | 536 | Income statement | Jun '22 | Jun '23 | Jun '24 | Jun '25 | Jun '26 |
| Makuutu 1xNAV sensitivity to recovery an | | E0.00 | | 50.00 | CE 011 | Revenue (US\$m) | | | | 53 | 396 |
| Makuutu NPV8% (US\$m) | Recov: 45.0% | 50.0% | 55.0% | 60.0% | 65.0% | COGS (US\$m) | | | | (41) | (283) |
| Payability: 60% | -36 | 28 | 89 | 146 | 202 | Gross profit (US\$m) | | | | 13 | 112 |
| Payability: 70% | 89 | 155 | 222 | 288 | 355 | Expenses (US\$m) | (3) | (4) | (1) | (2) | (5) |
| Payability: 80% | 201 | 278 | 354 | 431 | 508 | Impairment & other (US\$m) | | | | | |
| Payability: 90% | 313 | 400 | 487 | 574 | 661 | Net finance costs (US\$m) | 0 | | (7) | (8) | (5) |
| Payability: 100% | 425 | 522 | 619 | 716 | 813 | Tax (US\$m) | | | | (3) | (31) |
| Valuation over time | Jun '22 | Jun '23 | Jun '24 | Jun '25 | Jun '26 | Minority interest (US\$m) | | | | | |
| Makuutu NPV (US\$m) | 210.3 | 229.6 | 308.4 | 358.0 | 389.4 | Net income attr. (US\$m) | (3) | (4) | (9) | (1) | 72 |
| Downstream | 367.0 | 396.3 | 428.0 | 462.3 | 607.2 | EBITDA (US\$m) | (5) | (5) | (5) | 8 | 107 |
| Exploration and in-situ tonnes | 166.0 | 166.0 | 166.0 | 166.0 | 166.0 | Cash flow | Jun '22 | Jun '23 | Jun '24 | Jun '25 | Jun '26 |
| Cntrl G&A & fin costs (US\$m) | (50.3) | (50.6) | (52.1) | (45.0) | 2.3 | Profit/(loss) after tax (US\$m) | (5) | (5) | (12) | (8) | 62 |
| Net cash at 1Q (A\$m) | 19.6 | 86.8 | 41.8 | 26.3 | (156.9) | Add non-cash items (US\$m) | 1 | | | 4 | 10 |
| 1xNAV (US\$m) | 712 | 828 | 892 | 967 | 1,008 | Less wkg cap / other (US\$m) | (0) | | 9 | (1) | (57) |
| P/NAV (x): | 0.12x | 0.13x | 0.14x | 0.14x | 0.15x | Cash flow ops (US\$m) | (4) | (5) | (3) | (5) | 15 |
| 1xNAV share px FD (A\$/sh) | 0.29 | 0.26 | 0.25 | 0.24 | 0.22 | PP&E (US\$m) | | (3) | (79) | (184) | (198) |
| ROI to equity holder (% pa) | 750% | 177% | 94% | 63% | 46% | Other (US\$m) | (2) | (2) | | | |
| Sources and uses of cash | | | | | | Cash flow inv. (US\$m) | (11) | (6) | (79) | (184) | (198) |
| SCPe evaluation cos | | SCP | | sh + options | A\$36m | Debt draw (repayment) (US\$m) | | | 102 | 170 | |
| SCPe capex (US\$150m @ 60 | | | | ebt package | A\$102m | Equity issuance (US\$m) | 30 | 71 | 7 | 124 | |
| SCPe continger | , | | Ed | quity Raised | A\$62m | Other (US\$m) | | | | | |
| SCPe G&A + fin. cost to pro | | | | | | Cash flow fin. (US\$m) | 30 | 71 | 109 | 294 | |
| SCPe working capit | | | | | | Net change post forex (US\$m) | 16 | 60 | 27 | 104 | (183) |
| Total us | | | | tal proceeds | A\$200m | FCF (US\$m) | (13) | (8) | (82) | (189) | (183) |
| Production (100%) | Jun '24 | Jun '25 | Jun '26 | Jun '27 | Jun '28 | Balance sheet | Jun '22 | Jun '23 | Jun '24 | Jun '25 | Jun '26 |
| Makuutu (t REE) | | 929 | 2,149 | 2,901 | 3,868 | Cash (US\$m) | 27 | 87 | 114 | 218 | 35 |
| Makuutu (t Nd+Pr) | | 260 | 602 | 812 | 1,083 | Accounts receivable (US\$m) | 1 | 1 | 1 | 7 | 49 |
| Makuutu (t Dy) | | 28 | 64 | 87 | 116 | Inventories (US\$m) | | | | 7 | 35 |
| Makuutu (t Tb) | | 6 | 13 | 17 | 23 | PPE & exploration (US\$m) | 13 | 18 | 97 | 278 | 466 |
| Makuutu revenue (US\$/kg REE) | | 67 | 64 | 65 | 65 | Other (US\$m) | 9 | 9 | 9 | 9 | 9 |
| Makuutu cash cost (US\$/kg REE) | | 48 | 30 | 35 | 33 | Total assets (US\$m) | 49 | 115 | 221 | 520 | 594 |
| Makuutu AISC (US\$/REE) | | 67 | 46 | 51 | 49 | Debt (US\$m) | | | 102 | 272 | 272 |
| Refinery (TREO produced) | | | 1,722 | 3,110 | 4,311 | Other liabilities (US\$m) | 1 | 1 | 10 | 23 | 35 |
| Refinery (t Nd+Pr) | | | 898 | 1,259 | 1,726 | Shareholders equity (US\$m) | 77 | 148 | 155 | 279 | 279 |
| Refinery (t Dy) | | | 75 | 97 | 123 | Retained earnings (US\$m) | (29) | (34) | (46) | (53) | 9 |
| Refinery (t Tb) | | | 22 | 34 | 47 | Minority int. & other (US\$m) | | | | | |
| Refinery share of Makuutu feed (%) | | | 49% | 62% | 61% | Liabilities+equity (US\$m) | 49 | 115 | 221 | 520 | 594 |
| Refinery EBITDA margin (%) | | | 20% | 19% | 20% | Net cash (US\$m) | 27 | 87 | 12 | (53) | (236) |
| Refinery revenue (US\$/kg REO) | | | 114 | 98 | 110 | Net debt to NTM EBITDA (x) | 5.4x | 17.4x | (1.6x) | 0.5x | 1.6x |
| Common CCD antimosta | | | | | | | | | | | |

Source: SCP estimates

Equity Research

DISCLOSURES & DISCLAIMERS

This research report (as defined under IIROC Rule 3600, Part B) is issued and approved for distribution in Canada by Sprott Capital Partners LP ("SCP"), an investment dealer who is a member of the Investment Industry Regulatory Organization of Canada ("IROC") and the Canadian Investor Protection Fund ("CIPF"). The general partner of SCP is Sprott Capital Partners GP Inc. and SCP is a wholly-owned subsidiary of Sprott Inc., which is a publicly listed company on the Toronto Stock Exchange under the symbol "SII". Sprott Asset Management LP ("SAM"), a registered investment manager to the Sprott Funds and is an affiliate of SCP. This research report is provided to retail clients and institutional investors for information purposes only. The opinions expressed in this report are the opinions of the author and readers should not assume they reflect the opinions or recommendations of SCP's research department. The information in this report is drawn from sources believed to be reliable but the accuracy or completeness of the information is not guaranteed, nor in providing it does SCP and/or affiliated companies or persons assume any responsibility or liability whatsoever. This report is not to be construed as an offer to sell or a solicitation of an offer to buy any securities. SCP accepts no liability whatsoever for any loss arising from any use or reliance on this research report or the information contained herein. Past performance is not a guarantee of future results, and no representation or warranty, expressed or implied, is made regarding future performance of any security mentioned in this research report. The price of the securities mentioned in this research report and the income they generate may fluctuate and/or be adversely affected by market factors or exchange rates, and investors may realize losses on investments in such securities, including the loss of investment principal. Furthermore, the securities discussed in this research report may not be liquid investments, may have a high level of volatility or may be subject to additional and special risks associated with securities and investments in emerging markets and/or foreign countries that may give rise to substantial risk and are not suitable for all investors. SCP may participate in an underwriting of, have a position in, or make a market in, the securities mentioned herein, including options, futures or other derivatives instruments thereon, and may, as a principal or agent, buy or sell such products.

DISSEMINATION OF RESEARCH:

SCP's research is distributed electronically through email or available in hard copy upon request. Research is disseminated concurrently to a predetermined list of clients provided by SCP's Institutional Sales Representative and retail Investment Advisors. Should you wish to no longer receive electronic communications from us, please contact unsubscribe@sprott.com and indicate in the subject line your full name and/or corporate entity name and that you wish to unsubscribe from receiving research.

RESEARCH ANALYST CERTIFICATION:

Each Research Analyst and/or Associate who is involved in the preparation of this research report hereby certifies that:

- The views and recommendations expressed herein accurately reflect his/her personal views about any and all of the securities or issuers that are the subject matter of this research report;
- His/her compensation is not and will not be directly related to the specific recommendations or view expressed by the Research analyst in this research report;
- They have not affected a trade in a security of any class of the issuer within the 30-day period prior to the publication of this research report;
- They have not distributed or discussed this Research Report to/with the issuer, investment banking group or any other third party except for the sole purpose of verifying factual information; and
- They are unaware of any other potential conflicts of interest.

UK RESIDENTS:

Sprott Partners UK Limited ("Sprott") is an appointed representative of PillarFour Securities LLP which is authorized and regulated by the Financial Conduct Authority. This document has been approved under section 21(1) of the FMSA 2000 by PillarFour Securities LLP ("PillarFour") for communication only to eligible counterparties and professional clients as those terms are defined by the rules of the Financial Conduct Authority. Its contents are not directed at UK retail clients. PillarFour does not provide investment services to retail clients. PillarFour publishes this document as non-independent research which is a marketing communication under the Conduct of Business rules. It has not been prepared in accordance with the regulatory rules relating to independent research, nor is it subject to the prohibition on dealing ahead of the dissemination of investment research. It does not constitute a personal recommendation and does not constitute an offer or a solicitation to buy or sell any security. Sprott and PillarFour consider this note to be an acceptable minor non-monetary benefit as defined by the FCA which may be received without charge. This is because the content is either considered to be commissioned by Sprott's clients as part of their advisory services to them or is short term market commentary. Neither Sprott nor PillarFour nor any of its directors, officers, employees or agents shall have any liability, howsoever arising, for any error or incompleteness of fact or opinion in it or lack of care in its preparation or publication; provided that this shall not exclude liability to the extent that this is impermissible under the law relating to financial services. All statements and opinions are made as of the date on the face of this document and are not held out as applicable thereafter. This document is intended for distribution only in those jurisdictions where PillarFour is permitted to distribute its research.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by Sprott Capital Partners LP ("SCP"), a company authorized to engage in securities activities in Canada. SCP is not a registered broker/dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Sprott Global Resource Investments Ltd. ("SGRIL"), a broker dealer in the United States registered with the Securities Exchange Commission ("SEC"), the Financial Industry Authority ("FINRA"), and a member of the Securities Investor Protection Corporation ("SIPC"). Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through SCP.

SGRIL accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor. The analyst whose name appears in this research report is not licensed, registered, or qualified as a research analyst with FINRA and may not be an associated person of SGRIL and, therefore, may not be subject to applicable



Equity Research

restrictions under FINRA Rule 2241 regarding communications by a research analyst with a subject company, public appearances by the research analyst, and trading securities held by a research analyst account. To make further inquiries related to this report, United States residents should contact their SGRIL representative.

Analyst Certification/Regulation AC

The analyst and associate certify that the views expressed in this research report accurately reflect their personal views about the subject securities or issuers. In addition, the analyst and associate certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

Sprott Capital Partners Explanation of Recommendations: Should SCP issue research with recommendations, the research rating guidelines will be based on the following recommendations:

BUY: The stocks total returns are expected to be materially better than the overall market with higher return expectations needed for more risky securities markets

NEUTRAL: The stock's total returns are expected to be in line with the overall market

SELL: The stocks total returns are expected to be materially lower than the overall market

TENDER: The analyst recommends tendering shares to a formal tender offering

UNDER REVIEW: The stock will be placed under review when there is a significant material event with further information pending; and/or when the research analyst determines it is necessary to await adequate information that could potentially lead to a re-evaluation of the rating, target price or forecast; and/or when coverage of a particular security is transferred from one analyst to another to give the new analyst time to reconfirm the rating, target price or forecast.

NOT RATED ((N/R): The stock is not currently rated **NOT RATED ((N/R):** The stock is not currently rated

| Re | search Disclosure | Response | | | | |
|----|--|----------|--|--|--|--|
| 1 | SCP and its affiliates collectively beneficially owns 1% or more of any class of the issuer's equity securities ¹ | | | | | |
| 2 | The analyst or any associate of the analyst responsible for the report or recommendation or any individual directly involved in the preparation of the report holds or is short any of the issuer's securities directly or through derivatives | NO | | | | |
| 3 | An SCP partner, director, officer or analyst involved in the preparation of a report on the issuer, has during the preceding 12 months provided services to the issuer for remuneration other than normal course investment advisory or trading execution services | NO | | | | |
| 4 | SCP has provided investment banking services for the issuer during the 12 months preceding the date of issuance of the research report or recommendation | YES | | | | |
| 5 | Name of any director, officer, employee or agent of SCP who is an officer, director or employee of the issuer, or who serves in an advisory capacity to the issuer | NO | | | | |
| 6 | SCP is making a market in an equity or equity related security of the issuer | NO | | | | |
| 7 | The analyst preparing this report received compensation based upon SCP's investment banking revenue for the issuer | NO | | | | |
| 8 | The analyst has conducted a site visit and has viewed a major facility or operation of the issuer | YES | | | | |
| 9 | The analyst has been reimbursed for travel expenses for a site visit by the issuer | NO | | | | |

Sprott Capital Partners Equity Research Ratings:

| Summary of Recommendations as of January 2023 | | | | | |
|---|----|--|--|--|--|
| BUY: | 53 | | | | |
| HOLD: | 1 | | | | |
| SELL: | 0 | | | | |
| UNDER REVIEW: | 1 | | | | |
| TENDER: | 0 | | | | |
| NOT RATED: | 0 | | | | |
| | | | | | |
| TOTAL | 55 | | | | |

¹ As at the end of the month immediately preceding the date of issuance of the research report or the end of the second most recent month if the issue date is less than 10 calendar days after the end of the most recent month



Page 5